Review ArticleClinical StudiesR

Vitamin D3 Deficiency Results in Dysfunctions of Immunity with Severe Fatigue and Depression in a Variety of Diseases

ANNA DOROTHEA HÖCK
In Vivo January 2014, 28 (1) 133-145;

Abstract

Recent immune data on vitamin D3 deficiency help to more clearly understand chronic fatiguing illnesses, such as autoimmune disorders, cancer and chronic fatigue syndrome (CFS). The vitamin D3 pathway is activated by stress and requires sufficient stores of precursor 25-hydroxyvitamin D3 for proper cell and immune functions. In vitamin D3 deficiency, secretion of the antimicrobial peptide cathelicidin is reduced, leading to impaired auto/xenophagy. As a result, phagocytosis, cytotoxicity, antigen processing and antigen presentation become dysregulated. In addition, vitamin D3 deficiency affects T- and B-lymphocyte activation, as well as quantity, maturation and function of regulatory natural killer T-cells and their counterparts in the gut, i.e. T-cell receptor-αβ, cluster of differentiation-8αα-positive intraepithelial lymphocytes. Consequently, innate and adaptive immunity become de-regulated, with microbial effects contributing further to this. Persistent infections, chronic inflammation and fatigue follow. Vitamin D3 substitution in such conditions may help to prevent or to ameliorate such chronic conditions, even in patients with cancer.

Vitamin D3 and calcium deficiency are found in various diseases, including immune disorders (1-6) and in conditions with chronic fatigue (7-15). Some positive vitamin D treatment reports (11, 12, 15, 16), indicate a possible connection between vitamin D3 deficiency and chronic fatigue, exhaustion and depression. This article reviews immune reactivity as related to vitamin D3 levels, and energy de-regulation in vitamin D3 deficiency.

Sufficient Supply of Vitamin D3 is Important for Proper Human Cell Functions and Stress Response

Following light activation in the skin and further enzymatic processing, the active metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] of vitamin D3-precursor, also called calcitriol, is synthetized from the immediate pro-hormone 25-hydroxycholecalciferol (25OHD3) by the enzyme cytochrome p450-hydroxylase27B1 (CYP27B1). The reaction is mediated in the kidneys by parathormone and is calcium-dependent (17). This endocrine pathway serves in the tight regulation of serum calcium levels (5, 6, 17). However, most cells also convert 25OHD3 to active 1,25(OH)2D3, which serves as a para-, or autocrine transcription factor binding to many gene loci (17-22). In addition, 1,25(OH)2D3, in an epigenetic way, directly influences cell signals and cell functions (21, 23-25). 1,25(OH)2D3 is an important cell regulator and influences cell development, differentiation, proliferation and cell-cycle control (20, 21). Various kinds of cell stress cause activation of the vitamin D pathway, and generation of 1,25(OH)2D3 requires sufficient supply of the precursor 25OHD3 in order to establish an effective protective response (17, 22).

In particular, immune functions are highly dependent on 1,25(OH)2D3. Adequate functioning of immune cells depends on the vitamin D3 pathway as initiated by the expression of vitamin D receptor (VDR) and vitamin D-activating enzyme CYP27B1 (1, 5, 17, 26-29). In addition, 1,25(OH)2D3 mediates the induction of voltage-gated chloride and calcium ion channels, regulating the secretion of cellular products, e.g. transmitters and immune granules (23). The complex interplay of vitamin D3-induced effects leading to immune effectiveness and to balanced immune reactions are summarized in Figures 1, 2 and 3.

Physical and Functional Epithelial Barriers are Enhanced by 1,25(OH)2D3

At the first stage of defense at dermal and mucosal barriers, 1,25(OH)2D3 regulates gene expression of major proteins responsible for sealing epithelial tight junctions, i.e. claudins, thus stabilizing skin and mucosal barriers (28, 30-32). 1,25(OH)2D3 enhances keratin differentiation (33-34), modulates mitogen-activated protein kinase-signaling in keratinocytes by exerting anti-inflammatory and protective effects (35), and down-regulates matrix metalloproteinase-9 (36). Also 1,25(OH)2D3 protects against radiation effects (37), and against programmed cell death in stressed keratinocytes (38). 1,25(OH)2D3 reduces the responsiveness of interleukin-2(IL-2)-activated T-lymphocytes, thus diminishing stress-induced local inflammatory reactions (39).

Figure 1.
Figure 1.

Vitamin D3 repletion ensures effective microbial elimination, yet combined with prompt protective anti-inflammation and immunoregulation.

Influence of 1,25(OH)2D3 on Antimicrobial Peptides (AMiPs)

AMiPs are produced after a microbial challenge by epithelial cells, by natural killer cells (NK), γδ-T-lymphocytes, and also by B-lymphocytes (28, 29, 40, 41) serving as important biochemical barriers. AMiPs de-stabilize bacterial membranes by cationic and electrostatic effects (28, 29, 40). In addition, they are multifunctional and bind to certain cell signaling receptors and to DNA (42-45). They interact with immune, endothelial and epithelial cells (42, 46, 47), enhancing phagocytosis, auto/xenophagy, cellular cytotoxicity, chemoattraction of immune cells, induction of memory T-cells, angiogenesis and wound healing (28, 29, 40-42, 46, 47). AMiPs also possess immunoregulatory effects by suppressing pro-inflammatory cytokines, down-regulating toll-like receptor (TLR) expression, and by neutralizing endotoxins (27, 28, 42, 46, 47).

In humans, 1,25(OH)2D3 significantly enhances the expression of two antimicrobial peptides, called cathelicidin and defensin-4B (27-29, 40, 49, 50). Importantly, AMiPs act synergistically with 1,25(OH)2D3, enhancing innate immune functions, as well as down-regulating inflammation, and adaptive immune regulation. In a counter-measure, bacterial toxins reduce cathelicidin expression (51). Interestingly, in contrast to humans, mice devoid of sun exposure, regulate cathelicidin expression independently of 1,25(OH)2D3 (52).

Secretory immunoglobulin A (sIgA), another biochemical barrier of skin and mucosa, is supported by 1,25(OH)2D3 rather indirectly by inducing the expression of immunoglobulin A fragment crystallizable (IgA Fc) receptor on phagocytes leading to enhanced binding of sIgA (53-55). Furthermore, 1,25(OH)2D3 induces the C-C motif chemokine receptor-10 (CCR10) in human B-cells, resulting in enhanced B-cell differentiation to IgA-secretory cells, with potential for homing to the gut (56, 57).

Auto/Xenophagy as an Important Cellular Rheostat and its Relation to 1,25(OH)2D3 and Cathelicidin

Autophagy, in infection also named immuno- or xenophagy, is essential for cell and immune functioning (58-62). Damaged material (e.g. cell or tissue) is degraded in a multistep process, with its products being used for functional adaptation, recycling of building blocks, and energy production (58, 60). Autophagy functions like a rheostat, linking internal and external conditions to cell-regulatory pathways (60, 63).

Distinct autophagic steps (initiation/induction with nucleation; elongation and closure of the autophagosomal double-membrane; maturation and fusion with the lysosome), generate the auto(phago)lysosome, which degrades or extrudes the ingested material with greater efficacy than the phagolysosome (52, 58, 60, 62, 64). Three cell signaling systems initiate auto/xenophagy. Firstly, inhibition of mammalian target of rapamycin (mTOR)-AuTophaGy-related-1 (ATG1) complex; secondly, the beclin1/class III phosphoinositol-3 kinase C3/vacuolar protein sorting associated protein (PI3KC3)/VPS34) complex (58, 65); and thirdly, the AuTophaGy-related proteins ATG5-ATG12-ATG16L1 and ATG7-ATG3-ATG8/microtubule-associated protein 1A/1B-light chain 3 (LC3)/gamma-aminobutyric acid receptor-associated protein complex (GABARAP) (59). These signal systems respond to stress by activating TLRs, or nucleotide-binding oligomerization domain (NOD)-like receptors, nuclear factor-κB (NF-kB), and pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and tumor-necrosis factor-alpha (TNF-α), as well as by elevating intra- or subcellular calcium with subsequent activation of adenosine monophosphate-activated protein kinase (AMPK) (59, 63, 66, 67).

Importantly in autophagolysosomes, self- and non-self-peptides are joined to antigen-presenting molecules (58, 62), a process contributing substantially to immune control, anti-inflammatory activity, immune memory (59, 62, 68-70), and induction of self-tolerant T-cells (58, 65). Thymic epithelial cells and thymocytes use effective auto/xenophagy for positive and negative selection of T- and B-cells (71). De-regulated autophagy has been reported to result in autoimmune disease (62, 64) and cancer (63, 72).

Figure 2.
Figure 2.

The most important direct and indirect cooperative, and in part, bi-directional immune effects of vitamin D3 pathway. 25-OHD3 25-Hydoxyvitamin D3; 1,25(OH)2D3 1α,25-Dihydroxyvitamin D3; VDR vitamin D receptor; mDC myeloid dendritic cell, NK T-cells Natural Killer T-cells.

Figure 3.
Figure 3.

Vitamin D3-depletion results in a substantial innate immune defect, whereas the expected adaptive immune intolerance presumably is modified by microbial immune subversion mechanisms, characterized by marked immune tolerance, in spite of smoldering chronic inflammation. A hierarchy of further immune deregulation steps will ensue, culminating in the problem of chronic calcium deficiency with exacerbation of immunoderegulation.

1,25(OH)2D3 enhances auto/xenophagy at multiple levels, such as NOD2 receptor expression, ATG16L recruitment to the site of bacterial entry (73), or PI3KC3 activation, thus supporting initiation, nucleation and elongation of the autophagosomal membrane (64).

However, what is more efficient in auto/xenophagy, is the cooperation of both 1,25(OH)2D3 and cathelicidin (26, 49, 52, 64, 66, 67, 74, 75). Both agents enhance beclin-1 gene expression (66, 75, 76), and promote autophagosome maturation, as well as lysosomal fusion (26, 64, 74). They also increase acidity and protease activity in autophagolysosomes (66, 74). Interestingly, deranged autophagy compromises cathelicidin expression, revealing bi-directional coupling between cathelicidin and auto-xenophagy (64).

Auto/xenophagy further depends upon negative control mechanisms (77). Negative control regulators include members of the autophagy machinery itself such as ATG16L1 and ATG5-ATG12 complex, resulting in reduced production IL-1β, IL-18 and type I IFN-α (58, 62, 77). 1,25(OH)2D3 contributes to the negative control by inhibiting pro-inflammatory signals such as NF-kB, TNF-α, IFN-γ, and by promoting the cyclin-dependent kinase inhibitor P19INK4D (64).

Endo- and Phagocytosis are Enhanced by 1,25(OH)2D3 and Cathelicidin

1,25(OH)2D3 enhances endocytosis by augmented gene expression of antigen uptake receptors, including mannose receptor and FC-γ receptor II (CD32) (74, 78). Phagocytosis is promoted by 1,25(OH)2D3-mediated enhancement of macrophage maturation, lysosomal production of acid phosphatases and hydrogen superoxide (H2O2), and by enhanced xenophagy (1, 5, 28, 50, 79).

Although promoting endocytosis and phagocytosis, 1,25(OH)2D3 reduces antigen presentation, T-cell activation, and secretion of pro-inflammatory cytokines (80, 81). Cooperation of 1,25(OH)2D3, cathelicidin and auto-xenophagy optimizes neutralization of the endotoxin-induced pro-inflammatory TNF-α and nitric oxide production (42, 52, 75, 82).

1,25(OH)2D3 Induces Immune-tolerant Myeloid Dendritic Cells and Regulatory T-Cells

Innate and adaptive immunity are linked to dendritic cells (DCs) that orchestrate adaptive immune responses and anti-inflammatory regulation (56, 83, 84). The best known DC subtypes are myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells (56, 83, 85).

mDCs are antigen-presenting cells (86) and carry antigen-binding surface receptors of the major histocompatibility (MHC) group (83, 86, 87), as well as MHCI-like-receptors, such as the glycoprotein cluster of differentiation protein-1 family member (CD1d) (83). Activated mDCs secrete IL-12 (87, 88), and induce distinct T-cell populations such as Th1-cells for intracellular and Th17-cells for extracellular pathogens, and Th2-populations with regulatory T-cells (Treg) for incompletely-destroyed pathogens (86, 87).

Without activation, mDCs are highly dependent on 1,25(OH)2D3, which induces substantial immune tolerance (27, 56, 83, 84, 87, 89, 90). Immature mDCS, not yet stimulated, and their precursor cells express abundant VDRs, in contrast to stimulated mDCs. Hence, more differentiated mDCs, with less VDR expression, preserve their required defensive potential (56, 84, 88). However, even on antigenic stimulation, mDCs are more tolerant when 1,25(OH)2D3 is present (56, 84, 88, 89).

1,25(OH)2D3-induced immune tolerance is brought about by down-regulation of pro-inflammatory molecules in mDCs, such as CD40, CD80, CD86, MHCII, CD54, IL-12/IL-23p40 and the C-C motif chemokine ligand 17 (CCL17) (56, 84, 88). In addition, immune-inhibitory molecules are up-regulated including immunoglobulin-like transcript-3 (ILT3) and programmed death ligand-1 (PDL-1) (56, 84). As a result, mDCs secrete less IL-12, but more IL-10 and transforming growth factor (TGF) (26, 56, 91), thus promoting a shift from Th17 and Th9 to regulatory CD4+CD25+ Tregs (3, 92, 93). Tregs express increased inhibitory receptors including FOXP3 and cytotoxic lymphocytic antigen-4 (CTLA-4) (27, 84, 94, 95). Of interest is the mutual tolerance induction observed between DCs and Tregs (56, 96). However, the induction of a significant Th2-polarity by 1,25(OH)2D3 has been recently challenged (97).

1,25(OH)2D3-induced T-cell tolerance is also mediated by direct action on activated T-cells (26, 56, 98, 99). 1,25(OH)2D3 reduces the proliferative activity of Th1 cells by reducing the expression of pro-inflammatory cytokines such as IL-2, IFN-γ and TNF-α (56, 98-100). 1,25(OH)2D3 also enhances T-cell secretion of IL-4 and IL-13 (90) by inducing the stress and translation inhibitor protein cytidine-cytidine-adenosine-adenosine-thymidine box motif(CCAAT)/enhancer-binding protein (EBP) homologous protein (CHOP) (101, 102), and induces important Th2 transcription factors, such as signal transducer and activator of transcription-6, and GATA-binding protein, and CD 200, an immunoglobulin-like molecule on CD4+ T-lymphocytes, which inhibits Th17 differentiation (103).

Protective mucosal tolerance is also induced by 1,25(OH)2D3 by enhancing mucosal homing of immunoregulatory dendritic cells (1, 28, 104-106). Stress- and 1,25(OH)2D3-induced induction of vitamin D-up-regulating protein (VDUP1) additionally suppresses pro-inflammatory lymphocytes in the lamina propria (107).

In contrast to mDCs, pDCs are specialized for virus control via IFN-α secretion (56, 84, 89). They also induce Tregs, yet appear to be independent of 1,25(OH)2D3 (56). pDCs induce Tregs and adaptive immune tolerance in several ways: i) by up-regulation of inducible co-stimulatory ligand (ICOSL) with or without secretion of indoleamine 2,3-dioxygenase (IDO) (84, 108), ii) by up-regulated expression of IL-27, IL-10, and TGF-β1-mediated inhibition of Th17 polarization (84, 85), iii) by secretion of vasoactive intestinal polypeptide (VIP) in conditions such as chronic inflammation and/or autoimmunity (109), and iv) by thymic stromal lymphopoetin (TSLP) by pDCs or epithelial cells (84, 110). Tregs are also induced by retinoic acid (84, 111).

Cathelicidin and NK cells in Innate and Adaptive Immunity

NK cells are activated by direct DC/NK contact and cooperate with CD8+ cytotoxic T-cells (112, 113). Further activating signals in a bi-directional way may be received from and sent to macrophages, polymorphonuclear leucocytes, T- and B-lymphocytes, mast and epithelial cells, or as inhibitory signals from Tregs (112, 114, 115, 116). NK cells secrete antimicrobial peptides such as α-defensin and cathelicidin (48, 115, 117) and induce anti-inflammatory, immunoregulatory (118) and immune-memory effects (112, 113, 115). Their maturation and function depend upon the environmental signaling milieu (112-114, 118, 119). However, reliable in vivo evaluation of NK cell functions is limited by complex cell kinetics and variable signals from the surrounding environment (114, 120, 121). ‘Exhausted’ NK effector cells were described in chronic infectious processes (113).

Due to these complex relationships, reported effects of 1,25(OH)2D3 on NK cells remain contradictory. Some reports describe inhibitory effects (122), with depressed NK cell activation and cytotoxicity in rats (123-125), reduced NK cell chemotaxis against eosinophils, and reduced IL-15-induced IL-8 secretion (126). Others showed inhibition of NK cell activation by 1,25(OH)2D3, but no inhibition of cytotoxicity, with reversed inhibition after immune activation with IL-2 secretion or exogenous IL-2 addition (127, 128).

In apparent contrast, enhanced NK cell cytotoxicity was observed following treatment with active vitamin D3 (calcitriol) in patients on hemodialysis (129). Enhanced NK cytotoxicity towards cancer cells resulted from 1,25(OH)2D3-induced increase of cathelicidin (46, 48). Indirect positive effects on NK cytotoxicity were mediated by 1,25(OH)2D3-induced increase of glutathione synthesis (130, 131), and by 1,25(OH)2D3-induced increase of extracellular calcium levels with elevated activity of protein kinase C (PKC) and N-alpha-benzyl-oxycarbonyl-L-lysine thiobenzyl ester (BLT) esterase (132). In addition, NK cell differentiation and maturation was augmented by VDUP1 expression, an effect that could be further enhanced by differential cellular calcium influx (107, 133).

Vitamin D Receptor and 1,25(OH)2D3 Are most Important for Invariant NK T-cells

NK T-cells express NK and T-cell type-specific receptors (134, 135). Most NK T-cells belong to the subgroup of invariant NK T-cells, also called class I NK cells (110, 136-139), that resemble functionally of Tregs rather than NK cells (134, 135). They are regarded as being most essential for overall immune balance (134, 140, 141). The term ‘invariant’ refers to their semi-invariant special T-cell receptor (TCR), with an invariant alpha and a restricted beta chain (140). Differently from conventional T-cells, they constitutionally secrete IL-4 and IFN-γ, and augment secretion rapidly after immune challenge (134-136).

IL-4 is important for immune B-cell activation (142) and prevents immune overstimulation, chronic inflammation and autoimmunity (136). In contrast, IFN-γ is important for viral clearance, further immune activation, antimicrobial defense (143, 144) and phagosome maturation (52).

Like NK cells, invariant NK T-cells exert both immune-activating and immunoregulatory activity, and link innate and adaptive immune functions by a mutual and multi-dimensional cross-talk (145-148). They augment cytotoxic CD8+ T-cell responses by induction of CD70 expression on dendritic cells (147). Invariant NK T-cells consist of several subgroups with functional differences (145, 146). Their numbers appear reduced in certain autoimmune diseases (145, 146). Invariant NK T-cells are tightly connected to the vitamin D pathway (100, 136-139). Development and function of a double-positive intra-thymic invariant NK T-cell precursor depends exclusively on intra-thymic VDR expression and VDR-dependent induction of the non-classical MHCI receptor CD1d (100, 136-139). CD1d is structurally associated with β2-microglobulin, similar to the MHCI receptor (134, 140). CD1d receptor presents self-antigens, preferentially endogenous lipids and glycolipids (136, 138, 141). Invariant NK T-cells are self-reactive, but not self-destructive (134, 136-138). Whereas agonist selection of invariant NK T-cells is completed in the thymus, full maturation is completed in the periphery where invariant NK T-cells preferentially inhabit the liver and spleen (140, 141, 143, 145).

During their specific differentiation steps, invariant NK T-cells lose CD8, often also CD4 co-receptor (100). They begin to express NK lineage receptors, such as the activating type II integral membrane protein receptor (NKG2D), members of the Ly-49 family, and finally the natural killer (NK) cell-associated marker NK1.1 (CD161) (138) and the T-cell memory CD44 receptor (137). During these maturation steps, immunoregulatory properties with protection against pathogens, cancer and autoimmunity are acquired (145, 146). Interestingly, not only 1,25(OH)2D3, but also VDUP1 is required for invariant NK T-cell development (133).

Studies on mice with a knocked-out VDR revealed reduced invariant NK T-cell numbers and reduced IFN-γ and Il-4 secretion after antigen challenge (100, 136, 149, 150). Cell maturation was compromised, with inability to up-regulate CD44+ and NK1.1+ receptors (100, 138, 149-151). Vitamin D3-deficient wild-type mice had reduced numbers of invariant NK T-cells due to increased apoptosis in the thymus, yet after vitamin D3 supplementation had almost normal cellular function (100, 106, 138, 150). However, substitution of 1,25(OH)2D3 did not fully-restore invariant NK T-cell numbers, an effect even transferred to their offspring, possibly due to epigenetic changes induced by vitamin D3 deficiency (150).

Both VDR- and vitamin D-deficient animals were prone to develop inflammatory bowel disease and experimentally induced encephalomyelitis (32, 100, 106, 149).

Intra-epithelial CD8αα TCRαβ Cells are Invariant NK T-cell-equivalent gut Mucosa Cells and Essential for Local Immune Balance

In the gut epithelium, a cell population has been found to functionally resemble invariant NK T-cells (32, 100, 106, 136). They also develop from the same intra-thymic invariant NK T-precursor cell. Like invariant NK T-cells, they depend upon intra-thymic agonist selection, they are self-reactive without self-destruction, and exhibit phenotypes of regulatory or memory cells (32, 100). In contrast to invariant NK T-cells, they express a gut-specific homodimeric CD8+αα chain in the presence of IL-15 (152), and are identified as TCRαβ+CD8αα+ intraepithelial lymphocytes (100, 106, 136).

Gut mucosa of VDR-knockout animals contains only half as many CD8+αα cells, and the CD4/CD8αα intraepithelial lymphocytes are totally absent, presumably due to failed gut homing (3, 100, 106, 136).

Activated B-cells Express VDR, and B-cell/invariant NK T-cell Interactions Modulate Immune Responses

Activated B-cells, like activated T-cells, express VDR. Mediated by their antigen-specific B-cell receptor, B-lymphocytes also present antigens and support phagocytosis (153, 154). Finally, activated B-cells secrete cathelicidin, and by interaction with 1,25(OH)2D3 and cathelicidin, they contribute to optimal immune defense and balance (155, 156).

1,25(OH)2D3 directly inhibits B cell proliferation by stabilizing the cyclin-dependent kinase inhibitor p27 (157). It also inhibits the differentiation of ‘post-switch’ memory B-cells and plasma cells, and reduces immunoglobulin production and secretion, e.g. by inhibition of CD40 signaling (56, 157, 158), particularly of IgE (158). 1,25(OH)2D3 promotes B-lymphocyte apoptosis, IL-10 secretion, and expression of CCR10 (56, 157).

Of importance, several types of B-cell/invariant NK T-cell interactions have been reported. Firstly, invariant NK T-cells support B-cell antibody production and proliferation of memory B-cells, even without CD4-T-cell help (159). Secondly, invariant NK T-cells reduce proliferation and promote apoptosis of splenic self-reactive, CD1d- and IL-18-expressing marginal zone B-cells (MZBs) possessing innate autoimmune potential (160-163). Thirdly, invariant NK T-cells enhance proliferation of immunoregulatory follicular B-cells (162), while conversely, MZBs and DCs activate invariant NK T-cells (164).

In addition, high surface-expression of CD1d on immature B-cells appears essential for the proliferation and differentiation of invariant NK T-cells (165). Patients with systemic lupus erythematodes (SLE) have a B-cell-specific subcellular transport defect of CD1d causing reduced amounts of surface CD1d. They also have reduced invariant NK T-cell numbers with diminished IL-2 stimulation and diminished IFN-γ and TNF-α secretion, while IL-10 secretion is augmented (165). This transport defect was not found in other immune cells. An intrinsic invariant NK T-cell defect was excluded in these experiments. For unknown reasons, normal CD1d surface expression on other cell types, such as cortical thymocytes, lymph node mantle zone and spleen MZBs, and resting monocytes could not compensate for this SLE-specific intrinsic B-cell defect (165). Most interestingly, patients with SLE who responded to rituximab treatment showed restored CD1d characteristics in immature CD1dhi B-cells and normalization of invariant NK T-cell numbers, activation and function (165).

Discussion

As shown here, vitamin D3 levels, metabolism and physiological immunoreactivity are intimately related. Insufficient levels and activities of D3 can cause immune dysregulation, resulting in various diseases, and can negatively influence the course of a variety of diseases.

Initial symptoms of low 25OHD3 levels are intermittent fatigue and recurrent infections which remit seasonally or after holiday. Insidiously, chronic fatigue syndrome may develop over time, typically promoted by stressful and exhaustive life conditions, infections, traumatic or toxic injuries. Hallmarks of chronic fatigue syndrome/myalgic encephalopathy (CFS/ME) are severe and disabling fatigue, absence of fever in spite of general malaise resembling an acute infection, and exertion-induced aggravation of functional disabilities, as well as many additional symptoms, in particular generalized pain, sleep disorder, and gastrointestinal discomfort. Obvious organ damage is lacking, whereas reactive depressive symptoms prevail. Symptom shift to fibromyalgia (FMS) seems to be the rule when patients get older. Typically, FMS is correlated with chronic skeletal disorders of low inflammatory activity and neuropathic pains. Yet many people do not acquire CFS/ME or FMS. They suffer from clear-cut diseases that are supposed to be triggered by vitamin D3 deficiency or insufficiency. Usually, disabling fatigue accompanies chronic inflammatory and autoimmune diseases, as well as cancer, whereas less severe fatigue is usually reported by patients with chronic tissue de-generation. Severe chronic fatigue has also been observed in psychiatric diseases. Often, patients view fatigue as the most disabling among all the other disease symptoms.

Although clues are emerging that low 25OHD3 may cause chronic fatigue, altered lifestyle and behavior would also explain it, in particular with respect to patients who appear depressive or exhausted. Additionally, measurement of chronic fatigue is highly subjective. However, the diagnosis of depression or exhaustion is also subjective, in particular when the differential diagnosis of CFS/FMS or FMS is not considered. In contrast, in chronic inflammatory, autoimmune or malignant diseases, physicians appreciate fatigue undoubtedly as being disease-induced. In order to overcome usual prejudice against chronic fatigue, it should be considered that inflammation may not only induce fatigue, but also alteration of mitochondrial function, auto/xenophagy, or excitation-metabolism coupling due to lowered subcellular calcium stores (22, 166, 167).

Fortunately, an increasing number of authors acknowledge the importance of vitamin D in immunoregulation (168-180). Epidemiological studies report a correlation between an insufficient level of 25OHD3 and several immune diseases, such as chronic pulmonary infections (168-170), multiple sclerosis (171-174), SLE (175, 180), diabetes and cardiovascular diseases (22, 176), and cancer (7, 177-179). Additionally, low 25OHD3 levels and elevated immunoreactivity against Epstein-Barr virus were found before the onset of multiple sclerosis (171), and up-regulation of VDR and CYP27B1 was found in active lesions (174). Low 25OHD3 levels also correlated with recurrence of spinal inflammatory lesions (172), and reduced survival in ovarian cancer (179). Genetic variations in enzymes of the vitamin D pathway were found to augment the risk for multiple sclerosis (173), and differentiated thyroid carcinoma (178). Low 25OHD3 levels were also prevalent in patients with FMS and CFS (2, 6, 8, 9, 11, 12, 14, 15).

In contrast to these epidemiological studies, interventional studies are still rare and small-sized. After one-year treatment with 2,000 IU (50 μg)/day cholecalciferol, inflammatory and hemostatic markers and disease activity in SLE improved (180). A dose of 800 IU (20 μg) cholecalciferol/day applied for 2.5-10 months improved fatigue in patients with myasthenia gravis (10). Rehabilitation outcomes improved after vitamin D supplementation in those with multiple illnesses (16). 4,000 IU (100 μcg) cholecalciferol/day for one year reduced recurrent infections of the respiratory tract significantly (169). Importantly, a pilot study showed clearly improved mitochondrial oxidative function after normalization of 25OHD3 levels in 12 severely vitamin D3-deficient patients with chronic fatigue and myopathy (166). However, large interventional studies and clear evidence for usefulness of vitamin D3 treatment are still lacking. One cause of obvious reluctance to undertake larger interventional studies may be the ongoing debate and overall uncertainty about doses and possible side-effects of vitamin D3 treatment.

Timely diagnosis of underlying vitamin D3 deficiency or insufficiency and adequate treatment, even at the stage of unexplained chronic fatigue, is warranted. Measuring the blood levels of the precursor 25OHD3 is easy and cost-effective. In contrast, an elevated level of the active metabolite 1,25(OH)2D3 does not indicate vitamin D sufficiency, but might be an important clue to calcium deficiency, presumably associated with autoimmunity (2). Sufficiency is defined as 25OHD3 levels above 30-100 ng/ml (75-250 nmol/l). Levels of 10-30 ng/ml (25-75 nmol/l) indicate insufficiency, those below 10 ng/ml (25 nmol/l) clear-cut deficiency. Therapy is equally easy. Cholecalciferol can be applied orally, and continuous daily substitution is recommended. The therapeutic dose ranges from 4,000 to 10,000 IU (100-250 μg)/day. Higher doses of about 10,000 IU/day, and concurrent mineral, or other co-factor substitution are warranted in order to overcome eventual vitamin D3 resistance, such as in calcium deficiency. In contrast to drugs usually recommended for chronic inflammatory, autoimmune or malignant diseases, cholecalciferol is very inexpensive.

Early treatment of chronic fatigue and recurrent infections might prevent full-blown CFS/ME. Elevating 25OHD3 levels in early stages of diseases may ameliorate the course, and shorten the time needed for induction therapy, thus lowering total treatment costs. Deleterious side-effects, often life-threatening, of modern biological, cytostatic or immunosuppressive compounds may be avoided, or at least reduced. Incidence of relapse and treatment resistance may decrease, as well as the burden of disease, and therapy costs. However, usefulness and cost-effectiveness of vitamin D3 co-treatment needs further investigation from high-powered and carefully designed clinical studies.

Acknowledgements

I thank Gerhard RF Krueger MD PhD, UT – Houston Medical School, Houston, USA, for his support and advice in preparing this review.

Footnotes

  • Conflicts of Interest

    None.

  • Received September 9, 2013.
  • Revision received November 4, 2013.
  • Accepted November 6, 2013.

References

  1. ↵
    1. Adams JS,
    2. Ren S,
    3. Liu PT,
    4. Chun RF,
    5. Lagishetty V,
    6. Gombart AF,
    7. Borregaard N,
    8. Modlin RL,
    9. Hewison M
    : Vitamin D in defense of the human immune response. Ann NY Acad Sci 1117: 94-105, 2007.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Blaney GP,
    2. Albert PJ,
    3. Proal AD
    : Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann NY Acad Sci 1173: 384-390, 2009.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bruce D,
    2. Yu S,
    3. Ooi JH,
    4. Cantorna MT
    : Converging pathways lead to overproduction of IL-17 in the absence of vitamin D signaling. Int Immunol 23(8): 519-528, 2011.
    OpenUrlAbstract/FREE Full Text
    1. Hepburn AL
    : Adult coeliac disease: Rheumatic presentations are common. BMJ 335(7621): 627, 2007.
    OpenUrlFREE Full Text
  5. ↵
    1. Hewison M
    : Vitamin D and the immune system: New perspectives on an old theme. Endocrinol Metab Clin North Am 39(2): 365-379, 2010.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Holick MF,
    2. Chen TC
    : Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 87(4): 1080S-1086S, 2008.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Dev R,
    2. Del Fabbro E,
    3. Schwartz GG,
    4. Hui D,
    5. Palla SL,
    6. Gutierrez N,
    7. Bruera E
    : Preliminary report: Vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist 16(11): 1637-1641, 2011.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Antiel RM,
    2. Caudill JS,
    3. Burkhardt BE,
    4. Brands CK,
    5. Fischer PR
    : Iron insufficiency and hypovitaminosis D in adolescents with chronic fatigue and orthostatic intolerance. South Med J 104(8): 609-611, 2011.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Berkovitz S,
    2. Ambler G,
    3. Jenkins M,
    4. Thurgood S
    : Serum 25-hydroxy vitamin D levels in chronic fatigue syndrome: A retrospective survey. Int J Vitam Nutr Res 79(4): 250-254, 2009.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Askmark H,
    2. Haggård L,
    3. Nygren I,
    4. Punga AR
    : Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: A pilot study. Eur J Neurol 19(12): 1554-1560, 2012.
    OpenUrlPubMed
  11. ↵
    1. Gerwin RD
    : A review of myofascial pain and fibromyalgia-factors that promote their persistence. Acupunct Med 23(3): 121-134, 2005.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. De Meileir K,
    2. Patarca-Montero R
    1. Höck AD
    . Divalent cations, hormones, psyche and soma: Four case reports. In: Chronic Fatigue Syndrome. Critical Reviews and Clinical Advances. De Meileir K, Patarca-Montero R (eds.) New York, Haworth Medical Press. pp. 117-131, 2000.
    1. Hoskin L,
    2. Clifton-Bligh O,
    3. Hansen R,
    4. Fulcher G,
    5. Gates F
    : Bone density and body composition in young women with chronic fatigue. Ann N Y Acad Sci 904: 625-627, 2000.
    OpenUrlPubMed
  14. ↵
    1. Knutsen KV,
    2. Brekke M,
    3. Gjelstad S,
    4. Lagerløv P
    : Vitamin D status in patients with musculoskeletal pain, fatigue and headache: A cross-sectional descriptive study in a multi-ethnic general practice in Norway. Scand J Prim Health Care 28: 166-171, 2010.
    OpenUrlCrossRefPubMed
  15. ↵
    1. McCarty DE
    : Resolution of hypersomnia following identification and treatment of vitamin D deficiency. J Clin Sleep Med 6(6): 605-608, 2010.
    OpenUrlPubMed
  16. ↵
    1. Shinchuk LM,
    2. Holick MF
    : Vitamin D and rehabilitation: Improving functional outcomes. Nutr Clin Pract 22(3): 297-304, 2007.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Adams JS,
    2. Hewison M
    : Update in Vitamin D. J Clin Endocrinol Metab 95: 471-478, 2010.
    OpenUrlCrossRefPubMed
    1. Christakos S,
    2. Dhawan P,
    3. Porta A,
    4. Mady LJ,
    5. Seth T
    : Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol 347(1-2): 25-29, 2011.
    OpenUrlCrossRefPubMed
    1. Chun RF,
    2. Adams JS,
    3. Hewison M
    : Back to the future: A new look at ‘old’ vitamin D. J Endocrinol 198(2): 261-269, 2008.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Vitamin D
    1. Feldman D,
    2. Pike JW,
    3. Adams JS
    1. Haussler MR,
    2. Whitfield GK,
    3. Haussler CA,
    4. Hsieh JC,
    5. Jurutka PW
    . Nuclear vitamin D receptor: natural ligands, molecular structure-function, and transcriptional control of vital genes. In: Vitamin D. Third edition. Feldman D, Pike JW, Adams JS (eds.). New York, Academic Press, pp. 137-170, 2011.
  21. ↵
    1. Morris H A,
    2. Anderson PH
    : Autocrine and paracrine actions of vitamin D. Clin Biochem Rev 31: 129-138, 2010.
    OpenUrlPubMed
  22. ↵
    1. Peterlik M,
    2. Cross HS
    : Vitamin D and calcium insufficiency-related chronic diseases: Molecular and cellular pathophysiology. Eur J Clin Nutr 63(12): 1377-1386, 2009.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Feldman D,
    2. Pike JW,
    3. Adams JS
    1. Mizwicki MT,
    2. Norman AW
    . Vitamin D sterol/VDR conformational dynamics and nongenomic actions. In: Vitamin D. Third edition. Feldman D, Pike JW, Adams JS (eds.). New York, Academic Press, pp. 271-297, 2011.
    1. Norman AW
    : Minireview: New assignments for an already busy receptor. Endocrinology 147(12): 5542-5548, 2006.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Pike JW,
    2. Meyer MB
    : The vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-Dihydoxyvitamin D3. Rheum Dis Clin North Am 38(1): 13-27, 2012.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Hewison M
    : Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol 321(2): 103-111, 2010.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Kamen DL
    : Vitamin D and molecular actions on the immune system: Modulation of innate and autoimmunity. J Mol Med (Berl) 88(5): 441-450, 2010.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Feldman D,
    2. Pike JW,
    3. Adams JS
    1. Liu PT
    : The role of vitamin D in innate immunity: antimicrobial activity, oxidative stress, and barrier function. In: Vitamin D. Third edition. Feldman D, Pike JW, Adams JS (eds.) New York, Academic Press, pp. 1811-1823, 2011.
  29. ↵
    1. Feldman D,
    2. Pike JW,
    3. Adams JS
    1. White JH
    . Vitamin D and innate immunity. In: Vitamin D. Third edition. Feldman D, Pike JW, Adams JS (eds.). New York, Academic Press, pp. 1777-1787, 2011.
  30. ↵
    1. Fujita H,
    2. Sugimoto K,
    3. Inatomi S,
    4. Maeda T,
    5. Osanai M,
    6. Uchiyama Y,
    7. Yamamoto Y,
    8. Wada T,
    9. Kojima T,
    10. Yokozaki H,
    11. Yamashita T,
    12. Kato S,
    13. Sawada N,
    14. Chiba H
    : Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. Mol Biol Cell 19(5): 1912-1921, 2008.
    OpenUrlAbstract/FREE Full Text
    1. Kong J,
    2. Zhang Z,
    3. Musch MW,
    4. Ning G,
    5. Sun J,
    6. Hart J,
    7. Bissonnette M,
    8. Li YC
    : Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 294(1): G208-G216, 2008.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Sun J
    : Vitamin D and mucosal immune function. Curr Opin Gastroenterol 26(6): 591-595, 2010.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Ramot Y,
    2. Paus R,
    3. Tiede S,
    4. Zlotogorsky A
    : Endocrine controls of keratin expression. Bioassays 31(4): 389-399, 2009.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Zbytek B,
    2. Janjetovic Z,
    3. Tuckey RC,
    4. Zmijewski MA,
    5. Sweatman TW,
    6. Jones E,
    7. Nguyen MN,
    8. Slominski AT
    : 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 128(9): 2271-2280, 2008.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Miodovnik M,
    2. Koren R,
    3. Ziv E,
    4. Ravid A
    : The inflammatory response of keratinocytes and its modulation by vitamin D: The role of MAPK signaling pathways. J Cell Physiol 227(5): 2175-2183, 2012.
    OpenUrlPubMed
  36. ↵
    1. Bahar-Shany K,
    2. Ravid A,
    3. Koren R
    : Up-regulation of MMP-9 production by TNFα in keratinocytes and its attenuation by vitamin D. J Cell Physiol 222(3): 729-737, 2010.
    OpenUrlPubMed
  37. ↵
    1. Langberg M,
    2. Rotem C,
    3. Fenig E,
    4. Koren R,
    5. Ravid A
    : Vitamin D protects keratinocytes from deleterious effects of ionizing radiation. Br J Dermatol 160(1): 151-161, 2009.
    OpenUrlPubMed
  38. ↵
    1. Diker-Cohen T,
    2. Koren R,
    3. Ravid A
    : Programmed cell death of stressed keratinocytes and its inhibition by vitamin D: The role of death and survival signaling pathways. Apoptosis 11(4): 519-534, 2006.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Koren R,
    2. Liberman UA,
    3. Maron L,
    4. Novogrodsky A,
    5. Ravid A
    : 1,25-Dihydroxyvitamin D3 acts directly on human lymphocytes and interferes with the cellular response to interleukin-2. Immunopharmacology 18(3): 187-194, 1989.
    OpenUrlPubMed
  40. ↵
    1. Gombart AF
    : The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 4(9): 1151-1165, 2009.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Agerberth B,
    2. Charo J,
    3. Werr J,
    4. Olsson B,
    5. Idali F,
    6. Lindbom L,
    7. Kiessling R,
    8. Jörnvall H,
    9. Wigzell H,
    10. Gudmundsson GH
    : The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96(9): 3086-3093, 2000.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Alalwani SM,
    2. Sierigk J,
    3. Herr C,
    4. Pinkenburg O,
    5. Gallo R,
    6. Vogelmeier C,
    7. Bals R
    : The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol 40(4): 1118-1126, 2010.
    OpenUrlCrossRefPubMed
    1. Cederlund A,
    2. Gudmundsson GH,
    3. Agerberth B
    : Antimicrobial peptides important in innate immunity. FEBS J 278(20): 3942-3951, 2011.
    OpenUrlCrossRefPubMed
    1. Kai-Larsen Y,
    2. Agerberth B
    : The role of the multifunctional peptide LL-37 in host defense. Front Biosci 13: 3760-3767, 2008.
    OpenUrlPubMed
  45. ↵
    1. Yang D,
    2. Chertov O,
    3. Oppenheim JJ
    : The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adoptive immunity. Cell Mol Life Sci 58(7): 978-989, 2001.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Allaker RP
    : Host defence peptides_A bridge between the innate and adaptive immune responses. Trans R Soc Trop Med Hyg 102(1): 3-4, 2008.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Bowdish DM,
    2. Davidson DJ,
    3. Hancock RE
    : Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol 306: 27-66, 2006.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Büchau AS,
    2. Morizane S,
    3. Trowbridge J,
    4. Schauber J,
    5. Kotol P,
    6. Bui JD,
    7. Gallo RL
    : The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol 184(1): 369-378, 2010.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Campbell GR,
    2. Spector SA
    : Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. Autophagy 8(10): 1523-1525, 2012.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Di Rosa M,
    2. Malaguarnera M,
    3. Nicoletti F,
    4. Malaguarnera L
    : Vitamin D3: A helpful immune-modulator. Immunology 134(2): 123-139, 2011.
    OpenUrlCrossRefPubMed
  51. ↵
    1. McGillivray SM,
    2. Ebrahimi CM,
    3. Fisher N,
    4. Sabet M,
    5. Zhang DX,
    6. Chen Y,
    7. Haste NM,
    8. Aroian RV,
    9. Gallo RL,
    10. Guiney DG,
    11. Friedlander AM,
    12. Koehler TM,
    13. Nizet V
    : ClpX contributes to innate defense peptide resistance and virulence phenotypes of Bacillus anthracis. J Innate Immun (5): 494-506, 2009.
  52. ↵
    1. Fabri M,
    2. Stenger S,
    3. Shin DM,
    4. Yuk JM,
    5. Liu PT,
    6. Realegeno S,
    7. Lee HM,
    8. Krutzik SR,
    9. Schenk M,
    10. Sieling PA,
    11. Teles R,
    12. Montoya D,
    13. Iyer SS,
    14. Bruns H,
    15. Lewinsohn DM,
    16. Hollis BW,
    17. Hewison M,
    18. Adams JS,
    19. Steinmeyer A,
    20. Zügel U,
    21. Cheng G,
    22. Jo EK,
    23. Bloom BR,
    24. Modlin RL
    : Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci Transl Med 3(104): 104ra102, 2011.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Boltz-Nitulescu G,
    2. Willheim M,
    3. Spittler A,
    4. Leutmezer F,
    5. Tempfer C,
    6. Winkler S
    : Modulation of IgA, IgE, and IgG Fc receptor expression on human mononuclear phagocytes by 1 α,25-dihydroxyvitamin D3 and cytokines. J Leukoc Biol 58(2): 256-262, 1995.
    OpenUrlAbstract
    1. Maliszewski CR,
    2. Shen L,
    3. Fanger MW
    : The expression of receptors for IgA on human monocytes and calcitriol-treated HL-60 cells. J Immunol 135(6): 3878-3881, 1985.
    OpenUrlAbstract
  55. ↵
    1. Shen L,
    2. Maliszewski CR,
    3. Rigby WF,
    4. Fanger MW
    : IgA-mediated effector function of HL-60 cells following treatment with calcitriol. Mol Immunol 23(6): 611-618, 1986.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Feldman D,
    2. Pike JW,
    3. Adams JS
    1. Adorini L
    : Control of adaptive immunity by vitamin D receptor agonists. In: Vitamin D. Third edition. Feldman D, Pike JW, Adams JS (eds.). New York, Academic Press, pp. 1789-1809, 2011.
  57. ↵
    1. Shirakawa AK,
    2. Nagakubo D,
    3. Hieshima K,
    4. Nakayama T,
    5. Jin Z,
    6. Yoshie O
    : 1,25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B-cells. J Immunol 180(5): 2786-2795, 2008.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Deretic V,
    2. Levine B
    : Autophagy, immunity, and microbial adaptations. Cell Host Microbe 5(6): 527-549, 2009.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Deretic V
    : Autophagy as an innate immunity paradigm: Expanding the scope and repertoire of pattern recognition receptors. Curr Opin Immunol 24(1): 21-31, 2012.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Kroemer G,
    2. Mariño G,
    3. Levine B
    : Autophagy and the integrated stress response. Mol Cell 40(2): 280-293, 2010.
    OpenUrlCrossRefPubMed
    1. Mehrpour M,
    2. Esclatine A,
    3. Beau I,
    4. Codogno P
    : Autophagy in health and disease. 1. Regulation and significance of autophagy: An overview. Am J Physiol Cell Physiol 298: C776-C785, 2010.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Oh JE,
    2. Lee HK
    : Autophagy in innate recognition of pathogens and adaptive immunity. Yonsei Med J 53(2): 241-247, 2012.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Levine B,
    2. Kroemer G
    : Autophagy in the pathogenesis of disease. Cell 132(1): 27-42, 2008.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Wu S,
    2. Sun J
    : Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med 11(59): 325-335, 2011.
    OpenUrlPubMed
  65. ↵
    1. Choi AMK,
    2. Ryter SW,
    3. Levine B
    : Autophagy in human health and disease. N Engl J Med 368(7): 651-661, 2013.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Høyer-Hansen M,
    2. Bastholm L,
    3. Mathiasen IS,
    4. Elling F,
    5. Jäättelä M
    : Vitamin D analog EB1089 triggers dramatic lysosomal changes and beclin 1-mediated autophagic cell death. Cell Death Differentiation 12: 1297-1309, 2005.
    OpenUrlCrossRefPubMed
  67. ↵
    1. Høyer-Hansen M
    : AMP-activated protein kinase. A universal regulator of autophagy. Autophagy 3(4): 381-383, 2007.
    OpenUrlCrossRefPubMed
  68. ↵
    1. Glick D,
    2. Barth S,
    3. Macleod KF
    : Autophagy: Cellular and molecular mechanisms. J Pathol 221(1): 3-12, 2010.
    OpenUrlCrossRefPubMed
    1. He M-X,
    2. MacLeod IX,
    3. Jia W,
    4. He Y-W
    : Macroautophagy in T lymphocyte development and function. Front Immunol 3: 22, 2012
    OpenUrlPubMed
  70. ↵
    1. Ligeon LA,
    2. Temime-Smaali N,
    3. Lafont F
    : Ubiquitylation and autophagy in the control of bacterial infections and related responses. Cell Microbiol 13(9): 1303-1311, 2011.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Nedjic J,
    2. Aichinger M,
    3. Klein L
    : Autophagy and T cell education in the thymus: Eat yourself to know yourself. Cell Cycle 7(23): 3625-3628, 2008.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Winiarska M,
    2. Bil J,
    3. Nowis D,
    4. Golab J
    : Proteolytic pathways involved in modulation of CD20 levels. Autophagy 6(6): 810-812, 2010.
    OpenUrlPubMed
  73. ↵
    1. Travassos LH,
    2. Carneiro LA,
    3. Girardin S,
    4. Philpott DJ
    : Nod proteins link bacterial sensing and autophagy. Autophagy 6(3): 409-411, 2010.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Hmama Z,
    2. Sendide K,
    3. Talal A,
    4. Garcia R,
    5. Dobos K,
    6. Reiner NE
    : Quantitative analysis of phagolysosome fusion in intact cells: Inhibition by mycobacterial lipoarabinomannan and rescue by an 1α,25-Dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci 117: 2131-2139, 2004.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Yuk JM,
    2. Shin DM,
    3. Lee HM,
    4. Yang CS,
    5. Jin HS,
    6. Kim KK,
    7. Lee ZW,
    8. Lee SH,
    9. Kim JM,
    10. Jo EK
    : Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 6(3): 231-243, 2009.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Wang J
    : Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy 4(7): 947-948, 2008.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Liang C
    : Negative regulation of autophagy. Cell Death Differ 17(12): 1807-1815, 2010.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Chandra G,
    2. Selvaraj P,
    3. Jawahar MS,
    4. Banurekha VV,
    5. Narayanan PR
    : Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis. J Clin Immunol 24(3): 249-257, 2004.
    OpenUrlCrossRefPubMed
  79. ↵
    1. Abu-Amer Y,
    2. Bar-Shavit Z
    : Impaired bone marrow-derived macrophage differentiation in vitamin D deficiency. Cell Immunol 151(2): 356-368, 1993.
    OpenUrlCrossRefPubMed
  80. ↵
    1. Korf H,
    2. Wenes M,
    3. Stijlemans B,
    4. Takiishi T,
    5. Robert S,
    6. Miani M,
    7. Eizirik DL,
    8. Gysemans C,
    9. Mathieu C
    : 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T-cell-stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 217(12): 1292-1300, 2012.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Tokuda N,
    2. Levy RB
    : 1,25-Dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc Soc Exp Biol Med 211(3): 244-250, 1996.
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Zughaier SM,
    2. Shafer WM,
    3. Stephens DS
    : Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 7(9): 1251-1262, 2005.
    OpenUrlCrossRefPubMed
  83. ↵
    1. Blanco P,
    2. Palucka AK,
    3. Pascual V,
    4. Banchereau J
    : Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19(1): 41-52, 2008.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Kushwa R,
    2. Hu J
    : Role of dendritic cells in the induction of regulatory T-cells. Cell Biosci 1(1): 20, 2011.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Steinman RM,
    2. Hawiger D,
    3. Liu K,
    4. Bonifaz L,
    5. Bonnyay D,
    6. Mahnke K,
    7. Iyoda T,
    8. Ravetch J,
    9. Dhodapkar M,
    10. Inaba K,
    11. Nussenzweig M
    : Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann NY Acad Sci 987: 15-25, 2003.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Singh VK,
    2. Mehrotra S,
    3. Agarwal SS
    : The paradigm of Th1 and Th2 cytokines. Its relevance to autoimmunity and allergy. Immunol Res 20: 147-161, 1999.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Anderson M,
    2. Granum S
    1. Alberts B,
    2. Johnson A,
    3. Lewis J,
    4. Raff M,
    5. Roberts K,
    6. Walter P
    . The adaptive immune system. In: Molecular Biology of the Cell. Anderson M, Granum S (eds.). New York, Garland Science, pp. 1539-1601, 2008.
  88. ↵
    1. Canning MO,
    2. Grotenhuis K,
    3. de Wit H,
    4. Ruwhof C,
    5. Drexhage HA
    : 1-α,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 145(3): 351-357, 2001.
    OpenUrlAbstract
  89. ↵
    1. Adler HS,
    2. Steinbrink K
    : Tolerogenic dendritic cells in health and disease: Friend and foe! Eur J Dermatol 17(6): 476-491, 2007.
    OpenUrlPubMed
  90. ↵
    1. Sloka S,
    2. Silva C,
    3. Wang J,
    4. Yong VW
    : Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation 8: 56, 2011.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Jeffery LE,
    2. Burke F,
    3. Mura M,
    4. Zheng Y,
    5. Qureshi OS,
    6. Hewison M,
    7. Walker LSK,
    8. Lammas DA,
    9. Raza K,
    10. Sansom DM
    : 1,25-Dihydroxyvitamin D3 and Interleukin-2 combine to inhibit T-cell production of inflammatory cytokines and promote development of regulatory T-cells expressing CTLA-4 and FOXP3. J Immunol 183(9): 5458-5467, 2009.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Afzali B,
    2. Mitchell P,
    3. Lechler RI,
    4. John S,
    5. Lombardi G
    : Translational mini-review series on Th17 cells: Induction of interleukin-17 production by regulatory T-cells. Clin Exp Immunol 159(2): 120-130, 2010.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Prietl B,
    2. Pilz S,
    3. Wolf M,
    4. Tomaschitz A,
    5. Obermayer-Pietsch B,
    6. Graninger W,
    7. Pieber TR
    : Vitamin D supplementation and regulatory T-cells in apparently healthy subjects: Vitamin D treatment for autoimmune diseases? Isr Med Assoc J 12(3): 136-139, 2010.
    OpenUrlPubMed
  94. ↵
    1. Peterson RA
    : Regulatory T-cells: Diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 40(2): 186-204, 2012.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Schmidt SV,
    2. Nino-Castro AC,
    3. Schultze JL
    : Regulatory dendritic cells: There is more than just immune activation. Front Immunol 3: 274, 2012.
    OpenUrlCrossRefPubMed
  96. ↵
    1. Mahnke K,
    2. Ring S,
    3. Bedke T,
    4. Karakhanova S,
    5. Enk AH
    : Interaction of regulatory T-cells with antigen-presenting cells in health and disease. Chem Immunol Allergy 94: 29-39, 2008.
    OpenUrlCrossRefPubMed
  97. ↵
    1. Kreindler JL,
    2. Steele C,
    3. Nguyen N,
    4. Chan YR,
    5. Pilewski JM,
    6. Alcorn JF,
    7. Vyas YM,
    8. Aujla SJ,
    9. Finelli P,
    10. Blanchard M,
    11. Zeigler SF,
    12. Logar A,
    13. Hartigan E,
    14. Kurs-Lasky M,
    15. Rockette H,
    16. Ray A,
    17. Kolls JK
    : Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T-cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 120(9): 3242-3254, 2010.
    OpenUrlCrossRefPubMed
  98. ↵
    1. von Essen MR,
    2. Kongsbak M,
    3. Schjerling P,
    4. Olgaard K,
    5. Odum N,
    6. Geisler C
    : Vitamin D controls T-cell antigen receptor signaling and activation of human T-cells. Nat Immunol 11(4): 344-349, 2010.
    OpenUrlCrossRefPubMed
  99. ↵
    1. Willheim M,
    2. Thien R,
    3. Schrattbauer K,
    4. Bajna E,
    5. Holub M,
    6. Gruber R,
    7. Baier K,
    8. Pietschmann P,
    9. Reinisch W,
    10. Scheiner O,
    11. Peterlik M
    : Regulatory effects of 1α,25-Dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab 84(10): 3739-3744, 1999.
    OpenUrlCrossRefPubMed
  100. ↵
    1. Cantorna MT
    : Why do T-cells express the vitamin D receptor? Ann NY Acad Sci 1217: 77-82, 2011.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Chang SH,
    2. Chung Y,
    3. Dong C
    : Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 285(50): 38751-3855, 2010.
    OpenUrlAbstract/FREE Full Text
  102. ↵
    1. Joshi S,
    2. Pantalena LC,
    3. Liu XK,
    4. Gaffen SL,
    5. Liu H,
    6. Rohowsky-Kochan C,
    7. Ichiyama K,
    8. Yoshimura A,
    9. Steinman L,
    10. Christakos S,
    11. Youssef S
    : 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 31(17): 3653-3669, 2011.
    OpenUrlAbstract/FREE Full Text
  103. ↵
    1. Dimeloe S,
    2. Richards DF,
    3. Urry ZL,
    4. Gupta A,
    5. Stratigou V,
    6. Farooque S,
    7. Saglani S,
    8. Bush A,
    9. Hawrylowicz CM
    : 1α,25-Dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells. Thorax 67(7): 574-581, 2012.
    OpenUrlAbstract/FREE Full Text
  104. ↵
    1. Enioutina EY,
    2. Bareyan D,
    3. Daynes RA
    : TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. Vaccine 26(5): 601-613, 2008.
    OpenUrlCrossRefPubMed
    1. Ivanov AP,
    2. Dragunsky EM,
    3. Chumakov KM
    : 1,25-Dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 193(4): 598-600, 2006.
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Yu S,
    2. Bruce D,
    3. Froicu M,
    4. Weaver V,
    5. Cantorna MT
    : Failure of T-cell homing, reduced CD4/CD8αα intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci USA 105(52): 20834-20839, 2008.
    OpenUrlAbstract/FREE Full Text
  107. ↵
    1. Kim SY,
    2. Suh HW,
    3. Chung JW,
    4. Yoon SR,
    5. Choi I
    : Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. Cell Mol Immunol 4(5): 345-351, 2007.
    OpenUrlPubMed
  108. ↵
    1. Fallarino F,
    2. Grohmann U
    : Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T-cell functions. Curr Med Chem 18(15): 2215-2221, 2011.
    OpenUrlCrossRefPubMed
  109. ↵
    1. Delgado M
    : Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol 70(5): 300-307, 2009.
    OpenUrlCrossRefPubMed
  110. ↵
    1. Spadoni I,
    2. Iliev ID,
    3. Rossi G,
    4. Rescigno M
    : Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. Mucosal Immunol (2): 184-193, 2012.
  111. ↵
    1. Clark DA
    : Tolerance signaling molecules. Chem Immunol Allergy 89: 36-48, 2005.
    OpenUrlPubMed
  112. ↵
    1. Strowig T,
    2. Brilot F,
    3. Münz C
    : Non-cytotoxic functions of natural killer cells: Direct pathogen restriction and assistance to adaptive immunity. J Immunol 180(12): 7785-7791, 2008.
    OpenUrlAbstract/FREE Full Text
  113. ↵
    1. Vivier E,
    2. Raulet DH,
    3. Moretta A,
    4. Caligiuri MA,
    5. Zitvogel L,
    6. Lanier LL,
    7. Yokoyama WM,
    8. Ugolini S
    : Innate or adaptive immunity? The example of natural killer cells. Science 331(6013): 44-49, 2011.
    OpenUrlAbstract/FREE Full Text
  114. ↵
    1. Brady J,
    2. Carotta S,
    3. Thong RP,
    4. Chan CJ,
    5. Hayakawa Y,
    6. Smyth MJ,
    7. Nutt SL
    : The interactions of multiple cytokines control NK cell maturation. J Immunol 185(11): 6679-6688, 2010.
    OpenUrlAbstract/FREE Full Text
  115. ↵
    1. Souza-Fonseca-Guimaraes F,
    2. Adib-Conquy M,
    3. Cavaillon J-M
    : Natural killer (NK) cells in antibacterial innate immunity: angels or devils? Mol Med 18: 270-285, 2010.
    OpenUrl
  116. ↵
    1. Walzer T,
    2. Dalod M,
    3. Robbins SH,
    4. Zitvogel L,
    5. Vivier E
    : Natural-killer cells and dendritic cells: “l'union fait la force”. Blood 106(7): 2252-2258, 2005.
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Ravid A,
    2. Koren R,
    3. Maron L,
    4. Liberman UA
    : 1,25(OH)2D3 increases cytotoxicity and exocytosis in lymphokine-activated killer cells. Mol Cell Endocrinol 96(1-2): 133-139, 1993.
    OpenUrlCrossRefPubMed
  118. ↵
    1. Zafirova B,
    2. Wensveen FM,
    3. Gulin M,
    4. Polić B
    : Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Sci 68: 3519-3529, 2011.
    OpenUrl
  119. ↵
    1. Jamil KM,
    2. Khakoo SI
    : KIR/HLA interactions and pathogenic immunity. J Biomed Biotech 2011: 298348, 2011.
    OpenUrl
  120. ↵
    1. Ben-Eliyahu S
    : Can we really know if a stressor increases or decreases natural killer cell activity? Brain Behav Immun 26(8): 1224-1225, 2012.
    OpenUrlPubMed
  121. ↵
    1. Meron G,
    2. Tishler Y,
    3. Shaashua L,
    4. Rosenne E,
    5. Levi B,
    6. Melamed R,
    7. Gotlieb N,
    8. Matzner P,
    9. Sorski L,
    10. Ben-Eliyahu S
    : PGE(2) suppresses NK activity in vivo directly and through adrenal hormones: Effects that cannot be reflected by ex vivo assessment of NK cytotoxicity. Brain Behav Immun 28: 128-138, 2013.
    OpenUrlPubMed
  122. ↵
    1. Lemire JM
    : Immunomodulatory role of 1,25-Dihydroxyvitamin D3. J Cell Biochem 49(1): 26-31, 1992.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Kaneno R,
    2. Duarte AJ,
    3. Borelli A
    : Natural killer activity in the experimental privational rickets. Immunol Lett 81(3): 183-189, 2002.
    OpenUrlCrossRefPubMed
    1. Leung KH
    : Inhibition of human natural killer cell and lymphokine-activated killer cell cytotoxicity and differentiation by vitamin D3. Scand J Immunol 30(2): 199-208, 1989.
    OpenUrlCrossRefPubMed
  125. ↵
    1. Rebut-Bonneton C,
    2. Demignon J
    : Effect of calcitriol on peripheral blood lymphocyte cytotoxicity. Biomed Pharmacother 45(8): 369-372, 1991.
    OpenUrlPubMed
  126. ↵
    1. El-Shazly AE,
    2. Lefebvre P
    : Modulation of NK cell autocrine-induced eosinophil chemotaxis by interleukin-induced eosinophil chemotaxis by interleukin-15 and vitamin D3: A possible NK-eosinophil crosstalk via IL-8 in the pathophysiology of allergic rhinitis. Mediat Inflamm 2011: 373589, 2011.
    OpenUrl
  127. ↵
    1. Merino F,
    2. Alvarez-Mon M,
    3. de la Hera A,
    4. Alés JE,
    5. Bonilla F,
    6. Durantez A
    : Regulation of natural killer cytotoxicity by 1,25-Dihydroxyvitamin D3. Cell Immunol 118(2): 328-336, 1989.
    OpenUrlCrossRefPubMed
  128. ↵
    1. Tamori S,
    2. Uchiyama T,
    3. Uchino H
    : 1α,25-Dihydroxyvitamin D3 enhances the up-regulation of interleukin-2 receptor (p55) by interleukin-2. Nihon Ketsueki Gakkai Zasshi 52(6): 996-1003, 1989.
    OpenUrlPubMed
  129. ↵
    1. Quesada JM,
    2. Serrano I,
    3. Borrego F,
    4. Martin A,
    5. Peña J,
    6. Solana R
    : Calcitriol effect on natural killer cells from hemodialyzed and normal subjects. Calcif Tissue Int 56(2): 113-117, 1995.
    OpenUrlCrossRefPubMed
  130. ↵
    1. Garcion E,
    2. Sindji L,
    3. Leblondel G,
    4. Brachet P,
    5. Darcy F
    : 1,25-Dihydroxyvitamin D3 regulates the synthesis of γ-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem 73(2): 859-866, 1999.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Kechrid Z,
    2. Hamdi M,
    3. Naziroğlu M,
    4. Flores-Arce M
    : Vitamin D supplementation modulates blood and tissue zinc, liver glutathione and blood biochemical parameters in diabetic rats on a zinc-deficient diet. Biol Trace Elem Res 148(3): 371-377, 2012.
    OpenUrlPubMed
  132. ↵
    1. Balogh G,
    2. de Boland AR,
    3. Boland R,
    4. Barja P
    : Effect of 1,25(OH)2-vitamin D(3) on the activation of natural killer cells: Role of protein kinase C and extracellular calcium. Exp Mol Pathol 67(2): 63-74, 1999.
    OpenUrlCrossRefPubMed
  133. ↵
    1. Lee KN,
    2. Kang HS,
    3. Jeon JH,
    4. Kim EM,
    5. Yoon SR,
    6. Song H,
    7. Lyu CY,
    8. Piao ZH,
    9. Kim SU,
    10. Han YH,
    11. Song SS,
    12. Lee YH,
    13. Song KS,
    14. Kim YM,
    15. Yu DY,
    16. Choi I
    : VDUP1 is required for the development of natural killer cells. Immunity 22(2): 195-208, 2005.
    OpenUrlCrossRefPubMed
  134. ↵
    1. Issazadeh-Navikas S
    : NKT cell self-reactivity: Evolutionary master key of immune homeostasis? J Mol Cell Biol 4(2): 70-78, 2012.
    OpenUrlAbstract/FREE Full Text
  135. ↵
    1. Juno JA,
    2. Keynan Y,
    3. Fowke KR
    : Invariant NKT cells: Regulation and function during viral infection. PLOS Pathogens 8(8): e1002838, 2012.
    OpenUrlCrossRefPubMed
  136. ↵
    1. Cantorna MT
    : Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc 69(3): 286-289, 2010.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Yassai M,
    2. Cooley B,
    3. Gorski J
    : Developmental dynamics of post-selection thymic DN iNKT. PLoS One 7(8): e43509, 2012.
    OpenUrlPubMed
  138. ↵
    1. Yu S,
    2. Cantorna MT
    : The vitamin D receptor is required for iNKT cell development. Nat Acad Sci USA 105(13): 5207-5212, 2008.
    OpenUrlAbstract/FREE Full Text
  139. ↵
    1. Yue X,
    2. Izcue A,
    3. Borggrefe T
    : Essential role of mediator subunit MED 1 in invariant natural killer T-cell development. Proc Natl Acad Sci USA 108(41): 17105-17110, 2011.
    OpenUrlAbstract/FREE Full Text
  140. ↵
    1. Bendelac A,
    2. Savage PB,
    3. Teyton L
    : The biology of NKT cells. Annu Rev Immunol 25: 297-336, 2007.
    OpenUrlCrossRefPubMed
  141. ↵
    1. Brennan PJ,
    2. Tatituri RVV,
    3. Brigl M,
    4. Kim EY,
    5. Tuli A,
    6. Sanderson JP,
    7. Gadola SD,
    8. Hsu FF,
    9. Besra GS,
    10. Brenner MB
    : Invariant natural killer T-cells recognize lipid self-antigen induced by microbial danger signals. Nat Immunol 12(12): 1202-1211, 2012.
    OpenUrl
  142. ↵
    1. Morgan JW,
    2. Morgan DM,
    3. Lasky SR,
    4. Ford D,
    5. Kouttab N,
    6. Maizel AL
    : Requirements for induction of vitamin D-mediated gene regulation in normal human B-lymphocytes. J Immunol 157(7): 2900-2908, 1996.
    OpenUrlAbstract
  143. ↵
    1. Cecere TE,
    2. Todd SM,
    3. LeRoith T
    : Regulatory T-cells in Arterivirus and Coronavirus infections: Do they protect against disease or enhance it? Viruses 4: 833-846, 2012.
    OpenUrlPubMed
  144. ↵
    1. Pappworth IY,
    2. Wang EC,
    3. Rowe M
    : The switch from latent to productive infection in Epstein-Barr virus-infected B-cells is associated with sensitization to NK cell killing. J Virol 81(2): 474-482, 2007.
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Subleski JJ,
    2. Jiang Q,
    3. Weiss JM,
    4. Wiltrout RH
    : The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy 3(10): 1167-1184, 2011.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Watarai H,
    2. Sekine-Kondo E,
    3. Shigeura T,
    4. Motomura Y,
    5. Yasuda T,
    6. Satoh R,
    7. Yoshida H,
    8. Kubo M,
    9. Kawamoto H,
    10. Koseki H,
    11. Taniguchi M
    : Development and function of natural killer T-cells producing TH2- and TH17-cytokines. PLoS Biology 10(2): e1001255, 2012.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Taraban VY,
    2. Martin S,
    3. Attfield KE,
    4. Glennie MJ,
    5. Elliott T,
    6. Elewaut D,
    7. Van Calenbergh S,
    8. Linclau B,
    9. Al-Shamkhani A
    : Invariant NKT cells promote CD8+ cytotoxic T-cell responses by inducing CD70 expression on dendritic cells. J Immunol 180(7): 4615-4620, 2008.
    OpenUrlAbstract/FREE Full Text
  148. ↵
    1. Parietti V,
    2. Chifflot H,
    3. Sibilia J,
    4. Muller S,
    5. Monneaux F
    : Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 134(3): 331-339, 2010.
    OpenUrlCrossRefPubMed
  149. ↵
    1. Ooi JH,
    2. Chen J,
    3. Cantorna MT
    : Vitamin D regulation of immune function in the gut: Why do T-cells have vitamin D receptors? Mol Aspects Med 33(1): 77-82, 2012.
    OpenUrlCrossRefPubMed
  150. ↵
    1. Yu S,
    2. Cantorna MT
    : Epigenetic reduction in iNKT cells following in utero vitamin D deficiency in mice. J Immunol 186(3): 1384-1390, 2011.
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Gordy LE,
    2. Bezbradica JS,
    3. Flyak AI,
    4. Spencer CT,
    5. Dunkle A,
    6. Sun J,
    7. Stanic AK,
    8. Boothby MR,
    9. He YW,
    10. Zhao Z,
    11. Van Kaer L,
    12. Joyce S
    : IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 187(12): 6335-6345, 2011.
    OpenUrlAbstract/FREE Full Text
  152. ↵
    1. Ma LJ,
    2. Acero LF,
    3. Zal T,
    4. Schluns K
    : Trans-presentation of IL-15 by intestinal epithelial cells drives development of CD8αα IELs. J Immunol 183(2): 1044-1054, 2009.
    OpenUrlAbstract/FREE Full Text
  153. ↵
    1. Gao J,
    2. Ma X,
    3. Gu W,
    4. Fu M,
    5. An J,
    6. Xing Y,
    7. Gao T,
    8. Li W,
    9. Liu Y
    : Novel functions of murine B1 cells: Active phagocytic and microbicidal abilities. Eur J Immunol 42(4): 982-992, 2012.
    OpenUrlCrossRefPubMed
  154. ↵
    1. Qian L,
    2. Qian C,
    3. Chen Y,
    4. Bai Y,
    5. Bao Y,
    6. Lu L,
    7. Cao X
    : Regulatory dendritic cells program B-cells to differentiate into CD19hiFcγIIbhi regulatory B-cells through IFN-β and CD40L. Blood 120(3): 581-591, 2012.
    OpenUrlAbstract/FREE Full Text
  155. ↵
    1. Kin NW,
    2. Chen Y,
    3. Stefanov EK,
    4. Gallo RL,
    5. Kearney JF
    : Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function. Eur J Immunol 41(10): 3006-3016, 2011.
    OpenUrlCrossRefPubMed
  156. ↵
    1. Wuerth K,
    2. Hancock RE
    : New insights into cathelicidin modulation of adaptive immunity. Eur J Immunol 41(10): 2817-2819, 2011.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Chen S,
    2. Sims GP,
    3. Chen XX,
    4. Gu YY,
    5. Chen S,
    6. Lipsky PE
    : Modulatory effects of 1,25-Dihydroxyvitamin D3 on human B-cell differentiation. J Immunol 179: 1634-1647, 2007.
    OpenUrlAbstract/FREE Full Text
  158. ↵
    1. Geldmeyer-Hilt K,
    2. Heine G,
    3. Hartmann B,
    4. Baumgrass R,
    5. Radbruch A,
    6. Worm M
    : 1,25-Dihydroxyvitamin D3 impairs NF-kB activation in human naïve B-cells. Biochem Biophys Res Commun 407(4): 699-702, 2011.
    OpenUrlCrossRefPubMed
  159. ↵
    1. Galli G,
    2. Pittoni P,
    3. Tonti E,
    4. Malzone C,
    5. Uematsu Y,
    6. Tortoli M,
    7. Maione D,
    8. Volpini G,
    9. Finco O,
    10. Nuti S,
    11. Tavarini S,
    12. Dellabona P,
    13. Rappuoli R,
    14. Casorati G,
    15. Abrignani S
    : Invariant NKT cells sustain specific B-cell responses and memory. Proc Natl Acad Sci USA 104(10): 3984-3989, 2007.
    OpenUrlAbstract/FREE Full Text
  160. ↵
    1. Enoksson SL,
    2. Grasset EK,
    3. Hägglöf T,
    4. Mattsson N,
    5. Kaiser Y,
    6. Gabrielsson S,
    7. McGaha TL,
    8. Scheynius A,
    9. Karlsson MC
    : The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T-cells. Proc Natl Acad Sci USA 108(51): E1399-1407, 2011.
    OpenUrlAbstract/FREE Full Text
    1. Tonti E,
    2. Fedeli M,
    3. Napolitano A,
    4. Iannacone M,
    5. von Andrian UH,
    6. Guidotti LG,
    7. Abrignani S,
    8. Casorati G,
    9. Dellabona P
    : Follicular helper NKT cells induce limited B-cell responses and germinal center formation in the absence of CD4(+) T-cell help. J Immunol 188(7): 3217-3222, 2012.
    OpenUrlAbstract/FREE Full Text
  162. ↵
    1. Wen X,
    2. Yang JQ,
    3. Kim PJ,
    4. Singh RR
    : Homeostatic regulation of marginal zone B-cells by invariant natural killer T-cells. PLoS One 6(10): e26536, 2011.
    OpenUrlPubMed
  163. ↵
    1. Yang JQ,
    2. Wen X,
    3. Kim PJ,
    4. Singh RR
    : Invariant NKT cells inhibit autoreactive B-cells in a contact- and CD1d-dependent manner. J Immunol 186(3): 1512-1520, 2011.
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Bialecki E,
    2. Paget C,
    3. Fontaine J,
    4. Capron M,
    5. Trottein F,
    6. Faveeuw C
    : Role of marginal zone B-lymphocytes in invariant NKT cell activation. J Immunol 182(10): 6105-6113, 2009.
    OpenUrlAbstract/FREE Full Text
  165. ↵
    1. Bosma A,
    2. Abdel-Gadir A,
    3. Isenberg DA,
    4. Jury EC,
    5. Mauri C
    : Lipid-antigen presentation by CD1d+ B-cells is essential for the maintenance of invariant natural killer T-cells. Immunity 36(3): 477-490, 2012.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Sinha A,
    2. Hollingsworth KG,
    3. Ball S,
    4. Cheetham T
    : Improving the vitamin D status of vitamin D-deficient adults is associated with improved mitochondrial oxidative function in skeletal muscle. J Clin Endocrinol Metab 98(3): E509-513, 2013.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Rossi AE,
    2. Boncompagni S,
    3. Dirksen RT
    : Sarcoplasmic reticulum-mitochondrial symbiosis: Bi-directional signaling in skeletal muscle. Exerc Sport Sci Rev 37(1): 29-35, 2009.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Bergman P,
    2. Lindh AU,
    3. Björkhem-Bergman L,
    4. Lindh JD
    : Vitamin D and respiratory tract infections: A systematic review and meta-analysis of randomized controlled trials. PLoS One 8(6): e65835, 2013.
    OpenUrlCrossRefPubMed
  169. ↵
    1. Bergman P,
    2. Norlin AC,
    3. Hansen S,
    4. Rekha RS,
    5. Agerberth B,
    6. Björkhem-Bergman L,
    7. Ekström L,
    8. Lindh JD,
    9. Andersson J
    : Vitamin D3 supplementation in patients with frequent respiratory tract infections: A randomised and double-blind intervention study. BMJ Open 2(6): e001663, 2012.
    OpenUrlAbstract/FREE Full Text
  170. ↵
    1. Pfeffer PE,
    2. Hawrylowicz CM
    : Vitamin D and lung disease. Thorax 67(11): 1018-1020, 2012.
    OpenUrlAbstract/FREE Full Text
  171. ↵
    1. Décard BF,
    2. von Ahsen N,
    3. Grunwald T,
    4. Streit F,
    5. Stroet A,
    6. Niggemeier P,
    7. Schottstedt V,
    8. Riggert J,
    9. Gold R,
    10. Chan A
    : Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 83(12): 1170-1173, 2012.
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Mealy MA,
    2. Newsome S,
    3. Greenberg BM,
    4. Wingerchuk D,
    5. Calabresi P,
    6. Levy M
    : Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol 69(3): 352-356, 2012.
    OpenUrlCrossRefPubMed
  173. ↵
    1. Simon KC,
    2. Munger KL,
    3. Ascherio A
    : Vitamin D and multiple sclerosis: Epidemiology, immunology, and genetics. Curr Opin Neurol 25(3): 246-251, 2012.
    OpenUrlCrossRefPubMed
  174. ↵
    1. Smolders J,
    2. Schuurman KG,
    3. van Strien ME,
    4. Melief J,
    5. Hendrickx D,
    6. Hol EM,
    7. van Eden C,
    8. Luchetti S,
    9. Huitinga I
    : Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J Neuropathol Exp Neurol 72(2): 91-105, 2013.
    OpenUrlCrossRefPubMed
  175. ↵
    1. Fragoso TS,
    2. Dantas AT,
    3. Marques CD,
    4. Rocha Junior LF,
    5. Melo JH,
    6. Costa AJ,
    7. Duarte AL
    : 25-Hydroxyvitamin D3 levels in patients with systemic lupus erythematosus and its association with clinical parameters and laboratory tests. Rev Bras Reumatol 52(1): 60-65, 2012.
    OpenUrlPubMed
  176. ↵
    1. Eichhorn A,
    2. Lochner S,
    3. Belz GG
    : Vitamin D for prevention of diseases? Dtsch Med Wochenschr 137(17): 906-912, 2012. (in German)
    OpenUrlPubMed
  177. ↵
    1. Woloszynska-Read A,
    2. Johnson CS,
    3. Trump DL
    : Vitamin D and cancer: Clinical aspects. Best Pract Res Clin Endocrinol Metab 25(4): 605-615, 2011.
    OpenUrlCrossRef
  178. ↵
    1. Penna-Martinez M,
    2. Ramos-Lopez E,
    3. Stern J,
    4. Kahles H,
    5. Hinsch N,
    6. Hansmann ML,
    7. Selkinski I,
    8. Grünwald F,
    9. Vorländer C,
    10. Bechstein WO,
    11. Zeuzem S,
    12. Holzer K,
    13. Badenhoop K
    : Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. Thyroid 22(7): 709-716, 2012.
    OpenUrlPubMed
  179. ↵
    1. Walentowicz-Sadlecka M,
    2. Grabiec M,
    3. Sadlecki P,
    4. Gotowska M,
    5. Walentowicz P,
    6. Krintus M,
    7. Mankowska-Cyl A,
    8. Sypniewska G
    : 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clin Biochem 45(18): 1568-1572, 2012.
    OpenUrlPubMed
  180. ↵
    1. Abou-Raya A,
    2. Abou-Raya S,
    3. Helmii M
    : The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: A randomized placebo-controlled trial. J Rheumatol 40(3): 265-272, 2013.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Vitamin D3 Deficiency Results in Dysfunctions of Immunity with Severe Fatigue and Depression in a Variety of Diseases
ANNA DOROTHEA HÖCK
In Vivo Jan 2014, 28 (1) 133-145;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords